Leiden, The Netherlands, July 19, 2002 - Dutch antibody and vaccine company Crucell N.V. (Euronext, NASDAQ: CRXL) today announced that it has appointed Dr. Jaap Goudsmit to the Executive Committee as Chief Medical Officer and Executive Vice President Vaccine R&D.  Dr. Goudsmit will be responsible for product development and manufacturing, clinical and regulatory affairs and will remain the head of the Vaccine R&D division.

 

Dr. Goudsmit joined Crucell in September 2001 as Senior Vice President Vaccine Research. In this role he led Crucell's vaccine research program. Prior to joining Crucell, Dr. Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam, most recently holding the titles of chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Furthermore, Dr. Goudsmit has been appointed chairman to several national and international committees. Dr. Goudsmit is co-founder of both IAVI (International AIDS Vaccine Initiative), the premier non-governmental driving force for a global HIV vaccine, and EuroVac, the European Union AIDS vaccine effort to bring promising vaccine concepts to human testing. Dr. Goudsmit is currently chairman of the Scientific Advisory Committee of IAVI.

 

Dr. Goudsmit has authored over 450 publications and been a reviewer for a number of leading peer-reviewed journals. He is a board certified medical microbiologist and since 1989 full professor of virology at the University of Amsterdam. Dr. Goudsmit has taught and been a fellow at a number of institutions, such as the National Institutes of Health and New York University. He received a PhD in virology as well as a Medical Degree from the University of Amsterdam. Dr. Goudsmit remains affiliated with the University of Amsterdam and the Amsterdam Medical Center as professor of poverty-related communicable diseases.

 

About Crucell

Crucell discovers and develops biopharmaceuticals that use the human immune system to combat cancer, infectious diseases and other conditions.  Crucell leverages its patented technologies, MAbstract(TM), AdVac(TM), and PER.C6(TM), for discovery, development and production of antibodies and vaccines.  Crucell offers its technologies to the pharmaceutical and biotechnology industry and also uses them to create its own product pipeline.  Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and Centocor, a Johnson & Johnson company, for the CD46 antibody for treatment of various types of cancer.  In addition, Crucell has over 20 licensees for its PER.C6(TM) technology.  These include Novartis, GSK, Aventis and Schering AG.  With headquarters in Leiden, The Netherlands, the company currently employs 200 people.  Crucell is listed on Euronext and NASDAQ (ticker symbol CRXL).  For more information visit www.crucell.com.